Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API Services, have entered into a strategic partnership.

Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).   

The collaboration brings together Antheia's innovative biosynthesis platform with TAPI's advanced bioprocessing and manufacturing capabilities, enabling efficient, reliable and high-quality production of critical pharmaceutical ingredients at commercial scale.

Tapi’s existing infrastructure, capacity and quality management systems are expected to support Antheia's processes, enabling continuous growth and long-term support for multiple products in the company's pipeline.     

"As demand for Antheia's products continues to grow, our ability to both increase the scale of existing products and accelerate future product launches is critical," said Zack McGahey, COO of Antheia.

"With nearly a century of API manufacturing experience, TAPI brings a depth of expertise, as well as state-of-the-art infrastructure that will empower us to meet growing customer demand and deliver on our commercialisation strategy. Welcoming TAPI as a manufacturing partner will play a significant role in our efforts to transform pharmaceutical supply chains, end drug shortages and propel innovation in this space,” he added. 

R. Ananth, CEO of TAPI, said the partnership aligns closely with the company’s mission

"Our collaboration with Antheia reflects the essence of what we strive for at TAPI – Advancing Health from the Core and bringing together scientific innovation and manufacturing excellence to accelerate our partners' success. Through our flexible tech transfer model and collaborative, problem-solving approach, we're able to adapt seamlessly to our partners' needs and scale their innovations with confidence. Leveraging our Centre of Excellence for Biocatalysis and Enzyme Development, we're particularly excited to support Antheia's biosynthetic platform with the advanced fermentation and enzymatic capabilities that make these complex processes both efficient and commercially viable,” he added.